Simplify Logo

Full-Time

Bioinformatics Scientist

Solid Tumor DNA Oncology

Posted on 5/23/2024

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$120k - $140kAnnually

+ Incentive Compensation + Restricted Stock Units

Senior

San Carlos, CA, USA

Hybrid role with in-office presence required in Redwood City, CA.

Category
Bioinformatics
Computational Biology
Genomics
Biology & Biotech
Required Skills
Microsoft Azure
Data Structures & Algorithms
AWS
Data Analysis
Google Cloud Platform
Requirements
  • Ph.D. in Cancer Biology or Molecular Biology
  • Experience in cancer genetics
  • Experience working with next-generation sequencing data
  • Experience using workflow languages such as CWL and/or WDL
  • Experience using cloud systems such as AWS, Azure, and/or GCP
  • Self-driven and works well in interdisciplinary teams
  • Background in predictive or prognostic algorithm development
Responsibilities
  • Develop and optimize algorithms for cancer variation analysis
  • Design and conduct analysis to evaluate improvements in variant calling and data modeling
  • Validate oncology assays
  • Collaborate with scientists and clinicians for cancer clinical sequencing data analysis
  • Translate research into clinically actionable insights
  • Produce detailed documentation for projects

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in the healthcare sector. The company offers a platform that analyzes medical data, helping physicians make better treatment decisions by providing insights from medical images and identifying care gaps. For pharmaceutical and biotech companies, Tempus aids in drug development by discovering new targets and assessing treatment effectiveness. Patients benefit from personalized therapy options identified through the platform. Tempus conducts significant research, particularly in cancer, and has developed tools like a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. The company generates revenue by charging healthcare providers and companies for access to its platform and insights.

Company Stage

Series G

Total Funding

$1.3B

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

4%

1 year growth

13%

2 year growth

35%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tempus's IPO and significant revenue generation indicate strong financial health and growth potential.
  • Collaborations with industry giants like SoftBank and United Therapeutics can lead to groundbreaking advancements and increased market share.
  • The company's focus on personalized therapy and AI-driven insights can significantly improve patient outcomes, making it a rewarding place to work for those passionate about healthcare innovation.

What critics are saying

  • The lawsuit from Guardant Health over patent infringement could result in financial and reputational damage.
  • Operating in a highly competitive market with peers like Foundation Medicine and Guardant Health requires continuous innovation to maintain a competitive edge.

What makes Tempus unique

  • Tempus leverages AI to provide actionable insights from medical data, setting it apart from competitors who may not integrate AI as deeply into their platforms.
  • Their focus on personalized therapy options and extensive cancer research, including a pan-cancer organoid platform and liquid biopsy assay, distinguishes them in the healthcare tech space.
  • Tempus's collaboration with major firms like SoftBank and United Therapeutics highlights its strong industry partnerships and credibility.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE